Dermira, Inc. (NASDAQ:DERM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “

Other analysts have also issued research reports about the company. BidaskClub raised Dermira from a “strong sell” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald began coverage on Dermira in a report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price objective on the stock. Mizuho decreased their price objective on Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Evercore ISI began coverage on Dermira in a report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Four analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $43.80.

Dermira (NASDAQ DERM) traded up 0.34% during trading on Thursday, hitting $23.42. The stock had a trading volume of 294,759 shares. The company’s 50-day moving average is $27.27 and its 200 day moving average is $30.54. The firm’s market cap is $974.06 million. Dermira has a 52 week low of $21.35 and a 52 week high of $38.75.

Dermira (NASDAQ:DERM) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by $0.04. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1 million. Equities analysts expect that Dermira will post ($4.17) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/17/dermira-inc-derm-upgraded-by-zacks-investment-research-to-hold.html.

In related news, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $30.01, for a total value of $75,025.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Fred B. Craves purchased 30,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average cost of $23.03 per share, for a total transaction of $690,900.00. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 15,500 shares of company stock worth $446,715. 13.30% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in shares of Dermira by 4,816.7% in the first quarter. BlackRock Inc. now owns 3,392,848 shares of the biopharmaceutical company’s stock valued at $115,729,000 after buying an additional 3,323,841 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in shares of Dermira during the first quarter valued at approximately $20,296,000. Marshall Wace North America L.P. bought a new stake in shares of Dermira during the first quarter valued at approximately $20,296,000. Voya Investment Management LLC raised its stake in shares of Dermira by 61.4% in the second quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock valued at $35,783,000 after buying an additional 467,356 shares in the last quarter. Finally, Jana Partners LLC raised its stake in shares of Dermira by 171.0% in the first quarter. Jana Partners LLC now owns 655,252 shares of the biopharmaceutical company’s stock valued at $22,351,000 after buying an additional 413,442 shares in the last quarter. 83.82% of the stock is currently owned by institutional investors and hedge funds.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.